Method for obtaining crystalline 2′-fucosyllactose

    公开(公告)号:US11685759B2

    公开(公告)日:2023-06-27

    申请号:US17286474

    申请日:2019-10-17

    Applicant: BASF SE

    CPC classification number: C07H1/08 C07H3/06 C07B2200/13

    Abstract: The present invention relates to a method for obtaining crystalline 2′-fucosyllactose from a 2′-FL raw material, which contains 2′-FL as a main constituent and at least 0.5% by weight, frequently at least 1% by weight, in particular at least 2% by weight, more particularly at least 5% by weight, and especially at least 8% by weight,based on the total amount of mono-and oligosaccharides in the raw material, of one or more mono- or oligosaccharides different from 2′-FL, where the method comprises a)providing a solution of the 2′-FL raw material in water, which does not contain more than 10% by weight, preferably not more than 7% by weight, more preferably not more than 5% by weight of organic solvents, based on the total amount of water; b) effecting the crystallization of 2′-FL from the solution provided in step a) by inducing conditions of a controlled super saturation in the solution; and c) separating crystalline 2′-FL from the mother liquor, and where during controlled supersaturation in step b) not more than 10% by weight, preferably not more than 7% by weight, more preferably not more than 5% by weight of organic solvents are present, based on the total amount of water present during step b).

    CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDE

    公开(公告)号:US20220024898A1

    公开(公告)日:2022-01-27

    申请号:US17311403

    申请日:2020-01-10

    Applicant: BASF SE

    Abstract: The present invention relates to a novel crystalline form of 1-(1,2-dimethylpropyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide recently assigned the common name dimpropyridaz. The invention also relates to the use of the crystalline form B for combating invertebrate pests and to formulations for plant protection which contain the crystalline form B of 1-(1,2-dimethylpropyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide. The crystalline form B according to the present invention can be identified by powder X-ray diffractometry on the basis of its powder X-ray diffraction diagram, hereinafter also termed powder X-ray diffraction pattern or PXRD pattern, of the polymorph form B recorded using Cu—Kα radiation (1.54178 Å) at 25° C. displays the 3 following reflections, quoted as 2θ values: 20.69±0.10°, 24.15±0.10° and 30.52±0.10°. In addition to these 3 reflections, the polymorph B of the present invention may display in such a PXRD pattern one or more, in particular at least 2, often at least 4, in particular at least 6 or at least 8 reflections and especially all of the reflections quoted hereinafter as 2θ values: 7.99±0.10°, 10.07±0.10°, 12.38±0.10°, 15.31±0.10°, 15.97±0.10°, 16.50±0.10°, 18.03±0.10°, 19.29±0.10°, 20.22±0.0.10°, 20.96±0.10°, 23.40±0.10°, 23.70±0.10°, 26.09±0.10°, 27.26±0.10° and 32.91±0.10°.

Patent Agency Ranking